Tatva Chintan Pharma Chem block deals, bulk deals, insider trading and stake changes
NSE: TATVABSE: 543321Chemicals & PetrochemicalsSmall Cap
Last close ₹1,569.30down ₹94.80 (5.70%)BSE ₹1,572.10
Share price at the NSE close on 23 Oct 2026. Previous close ₹1,664.10.
52-week range of traded prices to 23 Oct 2026
₹1,044.10Low, 30 Mar 2026₹2,113.60High, 21 Oct 2026
- Under NSE's long-term additional surveillance, stage I, on the list for 23 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹3,671 Cr999th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 19 Oct 2026
- 58.3
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 19 Oct 2026
- 4.5
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.13%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 19 Oct 2026
- 8.0%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 19 Oct 2026
- 8.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026. The filing of 19 Oct 2026
- 0.21
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 2,50,09037.5% delivered
Promoter and insider buying and selling
Trades made since 23 Oct 2025.Tatva Chintan Pharma Chem promoter holding
No promoter, director, key manager or employee bought or sold on the market.
- Promoters and promoter group: no market trade · 2 off-market moves
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
Tatva Chintan Pharma Chem insider trading
All 7 disclosures on record.Insider trading, all companies
Feb 2026
- Ajay Mansukhlal Patel (HUF)7,15,345sharesGave · Promoter Group · 6 Feb 2026 · disclosed 9 Feb · Inter-se-Transfer · held 7,15,345 before
- Ajay Mansukhlal Patel7,15,345sharesReceived · Promoters · 6 Feb 2026 · disclosed 9 Feb · Inter-se-Transfer · stake 17.10% before, 20.16% after
Sep 2023
- Ajay Mansukhlal Patel₹1.18 Cr7,190 sharesSold · Promoters · 6 Sep 2023 · disclosed 7 Sep · stake 17.13% before, 17.10% after
- Darshana Nitinkumar Shah₹38 Cr2,33,766 sharesSold · Promoter Group · 6 Sep 2023 · disclosed 7 Sep · stake 1.17% before, 0.17% after
- Priti Ajay Patel₹3.35 Cr20,211 sharesSold · Promoter Group · 6 Sep 2023 · disclosed 7 Sep · stake 3.93% before, 3.85% after
- Ajay Mansukhlal Patel (HUF)₹34 Cr2,06,366 sharesSold · Promoter Group · 6 Sep 2023 · disclosed 7 Sep · stake 3.94% before, 3.06% after
- Shekhar Rasiklal Somani₹39 Cr2,33,767 sharesSold · Promoters · 6 Sep 2023 · disclosed 7 Sep · stake 24.07% before, 23.07% after
Trades by the company's promoters, directors, key managers, employees and their relatives, as each disclosed them. Value is what the filer stated; the mode is shown where the shares moved off the market.
Tatva Chintan Pharma Chem stake sales and purchases
All 9 disclosures on record.
Feb 2026
- AcquiredAjay Mansukhlal Patel along with pac · promoter3.06% of the company7,15,345 sharesholds 20.16% after6 Feb 2026 · filed under the 2% rule
- SoldAjay Mansukhlal Patel (HUF) along with pac · promoter3.06% of the company7,15,345 sharesholds none after6 Feb 2026 · filed under the 2% rule
Jul 2025
- SoldNippon India Mutual Fund0.12% of the company28,613 sharesholds 3.16% after4 Jul 2025 · filed under the 2% rule · Open Market
Sep 2023
- SoldPriti Ajay patel · promoter0.09% of the company20,211 sharesholds 3.85% after6 Sep 2023 · filed under the 2% rule · Open Market
- SoldDarshana Nitinkumar Shah · promoter1.00% of the company2,33,766 sharesholds 0.17% after6 Sep 2023 · filed under the 2% rule · Open Market
- SoldAjay Mansukhlal Patel · promoter0.03% of the company7,190 sharesholds 17.10% after6 Sep 2023 · filed under the 2% rule · Open Market
- SoldAjay Mansukhlal Patel (HUF) · promoter0.88% of the company2,06,366 sharesholds 7,15,345 shares after6 Sep 2023 · filed under the 2% rule · Open Market
- SoldShekhar Rasiklal Somani · promoter1.00% of the company2,33,767 sharesholds 23.07% after6 Sep 2023 · filed under the 2% rule · Open Market
Apr 2023
- AcquiredNippon Life India Trustee Limited A/c through Various Schemes of Nippon India Mutual Fund0.44% of the company96,631 sharesholds 5.27% after28 Apr 2023 · filed under the 5% rule · Open Market
The 5% rule: an investor discloses on reaching 5% of the company. The 2% rule: a holder of 5% or more discloses each change of 2% or more, including one that takes it below 5%. A transfer exempt from an open offer, the offer to buy from every other shareholder that a large purchase otherwise brings, is disclosed too. Each line shows what its filing states, which can be a smaller change than its rule names.
Tatva Chintan Pharma Chem block deals and bulk deals
None in the last 12 months, since 23 Oct 2025.Today's bulk and block deals, all companies
ValueValue of a deal. The shares traded times the deal's price.Per cent of the companyPer cent of the company. The shares traded as a percentage of all the company's shares in issue on the day of the deal.
Wednesday 15 Oct 20252 firms · ₹34 Cr bought · ₹34 Cr soldNet sold ₹0.03 Cr
- Both waysGRAVITON RESEARCH CAPITAL LLPBought 1,33,709 at ₹1,210.89Sold 1,33,709 at ₹1,212.740.57% of the companyNet nil₹16 Cr bought
- Both waysMUSIGMA SECURITIESBought 1,43,717 at ₹1,262.14Sold 1,43,717 at ₹1,262.510.61% of the companyNet nil₹18 Cr bought
Friday 25 Jul 20252 firms · ₹39 Cr bought · ₹39 Cr soldNet sold ₹0.05 Cr
- Both waysGRAVITON RESEARCH CAPITAL LLPBought 2,17,066 at ₹1,152.08Sold 2,17,066 at ₹1,153.920.93% of the companyNet nil₹25 Cr bought
- Both waysMUSIGMA SECURITIESBought 1,17,833 at ₹1,170.74Sold 1,17,833 at ₹1,171.360.50% of the companyNet nil₹14 Cr bought
Friday 18 Jul 20251 firm · ₹13 Cr bought · ₹13 Cr soldNet sold ₹80,364
- Both waysGRAVITON RESEARCH CAPITAL LLPBought 1,27,562 at ₹1,035.16Sold 1,27,562 at ₹1,035.790.55% of the companyNet nil₹13 Cr bought
Wednesday 6 Sep 20234 firms · ₹20 Cr bought · ₹111 Cr soldNet sold ₹90 Cr
- SoldSHEKHAR RASIKLAL SOMANISold 2,33,767 at ₹1,647.831.00% of the company₹39 Cr
- SoldDARSHANA NITINKUMAR SHAHSold 2,33,766 at ₹1,639.601.00% of the company₹38 Cr
- SoldAJAY MANSUKHLAL PATEL HUFSold 2,06,366 at ₹1,642.120.88% of the company₹34 Cr
- BoughtDAKSHA DUSHYANT PATELBought 1,24,000 at ₹1,646.030.53% of the company₹20 Cr
Friday 27 Aug 20212 firms · ₹20 Cr bought · ₹20 Cr soldNet nil
- BoughtGOLDMAN SACHS FUNDS GOLDMAN SACHS INDIA EQUITY PORTFOLIOBlock dealBought 92,339 at ₹2,129.70₹20 Cr
- SoldGOLDMAN SACHS INDIA FUND LIMITEDBlock dealSold 92,339 at ₹2,129.70₹20 Cr
Thursday 29 Jul 20215 firms · ₹402 Cr bought · ₹261 Cr soldNet bought ₹141 Cr
- BoughtPLUTUS WEALTH MANAGEMENT LLPBought 6,50,000 at ₹2,171.74₹141 Cr
- Both waysNK SECURITIES RESEARCH PRIVATE LIMITEDBought 5,81,308 at ₹2,337.65Sold 5,81,308 at ₹2,340.16Net nil₹136 Cr bought
- Both waysNUMIV RESEARCH PRIVATE LIMITEDBought 2,47,676 at ₹2,317.81Sold 2,47,676 at ₹2,319.84Net nil₹57 Cr bought
- Both waysALPHAGREP SECURITIES PRIVATE LIMITEDBought 1,49,145 at ₹2,329.07Sold 1,49,145 at ₹2,328.08Net nil₹35 Cr bought
- Both waysVAIBHAV STOCK AND DERIVATIVES BROKING PRIVATE LIMITEDBought 1,40,469 at ₹2,325.08Sold 1,40,469 at ₹2,326.07Net nil₹33 Cr bought
A bulk deal is one client trading half a per cent or more of the shares in a day; a block deal is a large trade in the exchange's separate block window, its buyer and its seller each on a line of their own. A firm that bought and sold the shares the same day is on one line, with its net. All 24 deals on record since listing on 29 Jul 2021.